Traitement du PTI et de l’AHAI au cours du DICV : revue systématique de la littérature by V. Lacombe et al.
Traitement du PTI et de l’AHAI au cours du DICV : revue
systématique de la littérature
Submitted by Stéphanie Pinot on Tue, 07/02/2019 - 15:00
Titre Traitement du PTI et de l’AHAI au cours du DICV : revue systématique de la littérature
Type de
publication Article de revue
Auteur Lacombe, V [1], Lozac'h, P [2], Orvain, Corentin [3], Lavigne, Christian [4], Miot,Charline [5], Pellier, Isabelle [6], Urbanski, Geoffrey [7]
Editeur Elsevier








revue La Revue de Médecine Interne
ISSN 1768-3122
Mots-clés Auto-immune cytopenias [8], Auto-immune hemolytic anemia [9], Common variableimmunodeficiency [10], Immune thrombocytopenia [11]
Résumé en
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INTRODUCTION: Ten to 15% of common variable immunodeficiencies (CVID) develop
auto-immune hemolytic anemia (AIHA) and immune thrombocytopenia (ITP).
Treatment is based on immunosuppressants, which produce blocking effects in the
CVID. Our objective was to assess their risk-benefit ratio in these
immunocompromised patients.
METHODS: We identified 17 articles detailing the treatment of AIHA and/or ITP in
patients suffering from CVID through a systematic review of the MEDLINE database.
RESULTS: The increased infectious risk with corticosteroids does not call into
question their place in the first line of treatment of ITP and AIHA in CVID. High-doses
immunoglobulin therapy remain reserved for ITP with a high risk of bleeding. In
second-line treatment, rituximab appears to be effective, with a lower infectious risk
than the splenectomy. Immunosuppressants (azathioprine, methotrexate,
mycophenolate, cyclophosphamide, vincristine, ciclosporine) are moderately effective
and often lead to severe infections, meaning that their use is justified only in resistant
cases and steroid-sparing. Dapsone, danazol and anti-D immunoglobulins have an
unfavorable risk-benefit ratio. The place of TPO receptor agonists is still to be defined.
The establishment of immunoglobulin replacement in the place of
immunosuppressants (except for short-term corticotherapy) or splenectomy appears to
be essential to limit the risk of infections, including in the absence of previous
infections.
CONCLUSION: The presence of CVID does not mean that it is necessary to give up on
corticosteroids as a first-line treatment and rituximab as a second-line treatment for
AIHA and ITP, but it should be in addition to immunoglobulin replacement. A
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